Deferred Tax Assets, Valuation Allowance in USD of Vincerx Pharma, Inc. from Q4 2019 to Q4 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
Summary
Vincerx Pharma, Inc. quarterly Deferred Tax Assets, Valuation Allowance history and growth rate from Q4 2019 to Q4 2024.
  • Vincerx Pharma, Inc. Deferred Tax Assets, Valuation Allowance for the quarter ending December 31, 2024 was $41M, a 8.49% increase year-over-year.
Deferred Tax Assets, Valuation Allowance, Quarterly (USD)
Deferred Tax Assets, Valuation Allowance, YoY Quarterly Growth (%)

Vincerx Pharma, Inc. Quarterly Deferred Tax Assets, Valuation Allowance (USD)

Period Value YoY Chg Change % Date Report Filed
Q4 2024 $41M +$3.21M +8.49% Dec 31, 2024 10-K 2025-03-27
Q4 2023 $37.7M +$9.39M +33.1% Dec 31, 2023 10-K 2025-03-27
Q4 2022 $28.4M +$12.9M +83.7% Dec 31, 2022 10-K 2024-03-29
Q4 2021 $15.4M +$12.4M +412% Dec 31, 2021 10-K 2023-03-28
Q4 2020 $3.02M -$9.99M -76.8% Dec 31, 2020 10-K 2022-03-29
Q2 2020 $25.7K* Jun 30, 2020 10-K 2020-09-23
Q4 2019 $13M Dec 31, 2019 10-K/A 2021-05-14
* An asterisk sign (*) next to the value indicates that the value is likely invalid.